Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) in 1L DLBCL Announced January 11, 2026
Ziihera (zanidatamab-hrii) Results in 1L HER2+ Locally Advanced or Metastatic GEA Announced Including 2+ Years Median OS Benefit January 11, 2026
64% OS At 12 Months Announced in 1L Pancreatic Cancer Patients Treated with Atebimetinib + mGnP January 11, 2026
Fourth consecutive case of response from Ph 1 data for the combination of AB8939 with venetoclax in R/R AML reported January 11, 2026
Data Reported from Ongoing Ph 2a study for BI-1808 with KEYTRUDA in Recurrent Ovarian Cancer January 4, 2026
FAILED TRIAL: LATIFY Ph 3 trial of ceralasertib + Imfinzi did not meet the OS primary endpoint vs SOC docetaxel in NSCLC patients December 30, 2025
12-Month OS Data from Ph 2a Trial of Atebimetinib + mGnP in 1L Pancreatic Cancer Patients to be announced on Jan 7, 2026 December 30, 2025
Preliminary Analysis Shows 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 December 22, 2025
ANKTIVA® with BCG Demonstrates 96% Survival at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only NMIBC December 22, 2025
Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic CRC Announced December 22, 2025
Clinical Activity of MRT-2359 + Enzalutamide Combo in Heavily Pretreated Metastatic CRPC Patients with Androgen Receptor Mutations Announced December 22, 2025
PADCEV + Keytruda combo Significantly Improves Survival for MIBC Patients Regardless of Cisplatin Eligibility December 22, 2025
NCCN® Duvelisib (COPIKTRA®) Update to Clinical Practice Guidelines in Oncology for CTCL December 22, 2025
Encouraging Clinical Results with In Situ Conversion Therapy NXL-004 for Malignant Glioma Reported December 22, 2025
Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma December 15, 2025
New Analyses of DUBLIN-3 Ph 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for NonSq EGFR WT NSCLC and a Reduction in Brain Mets Compared to Docetaxel Announced December 15, 2025
Updated Efficacy Data of Ivonescimab Combined with Chemo as 1L Treatment for TNBC Presented December 15, 2025
FAILED TRIAL: Ph 3 STAR-221 study of domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility December 15, 2025
Six-Year JUPITER-02 Follow-up Results Show LOQTORZI® plus Chemo Nearly Doubles Median OS in NPC December 9, 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant OS improvement for Asian patients with EGFR-mutated NSCLC in the Ph 3 MARIPOSA study December 9, 2025
Results from Ph 2 POC study of HLX43 in recurrent/metastatic cervical cancer published December 9, 2025
Additional Positive LP-184 Ph 1a Results Reported Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients December 9, 2025
